These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12874508)

  • 21. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
    In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-[1-11C]-tyrosine PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma and skin cancer.
    van Ginkel RJ; Kole AC; Nieweg OE; Molenaar WM; Pruim J; Koops HS; Vaalburg W; Hoekstra HJ
    J Nucl Med; 1999 Feb; 40(2):262-7. PubMed ID: 10025833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.
    Lasithiotakis K; Economou G; Gogas H; Ioannou C; Perisynakis K; Filis D; Kastana O; Bafaloukos D; Decatris M; Catodritis N; Frangia K; Papadakis G; Magarakis M; Tsoutsos D; Chrysos E; Chalkiadakis G; Zoras O
    Oncol Rep; 2010 Apr; 23(4):1077-83. PubMed ID: 20204294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities.
    Taeger G; Grabellus F; Podleska LE; Müller S; Ruchholtz S
    Int J Hyperthermia; 2008 May; 24(3):193-203. PubMed ID: 18392998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alteration of tissue oxygen partial pressure during isolated, hyperthermic limb perfusion with cytostatic drugs or recombinant human tumor necrosis factor alpha combined with melphalan.
    Hohenberger P; Bida B; Schlag PM
    Strahlenther Onkol; 1996 Nov; 172 Suppl 2():14-5. PubMed ID: 8946039
    [No Abstract]   [Full Text] [Related]  

  • 26. Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation.
    Stamatiou D; Ioannou CV; Kontopodis N; Michelakis D; Perisinakis K; Lasithiotakis K; Zoras O
    J Surg Res; 2017 Jun; 213():147-157. PubMed ID: 28601307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotoxicity of isolated limb perfusion with tumor necrosis factor.
    Drory VE; Lev D; Groozman GB; Gutmann M; Klausner JM
    J Neurol Sci; 1998 Jun; 158(1):1-4. PubMed ID: 9667770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
    Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
    In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current uses of isolated limb perfusion in the clinic and a model system for new strategies.
    Eggermont AM; de Wilt JH; ten Hagen TL
    Lancet Oncol; 2003 Jul; 4(7):429-37. PubMed ID: 12850194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
    Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperthermic isolated limb perfusion for extremity sarcomas.
    Kim CJ; Puleo C; Letson GD; Reintgen D
    Cancer Control; 2001; 8(3):269-73. PubMed ID: 11378653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan on pulmonary function assessments.
    Sleijfer S; van Ginkel RJ; van der Mark TW; Hoekstra HJ; Zwaveling JH; Schraffordt Koops H; Mulder NH
    J Immunother; 1997 May; 20(3):202-7. PubMed ID: 9181458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperthermic isolated perfusion with low-dose TNFalpha and doxorubicin in patients with locally advanced soft tissue limb sarcomas.
    Rossi CR; Foletto M; Mocellin S; Pilati P; Quintieri L; De Salvo GL; Nitti D; Lise M
    J Chemother; 2004 Nov; 16 Suppl 5():58-61. PubMed ID: 15675481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
    Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
    Jakob J; Hohenberger P
    Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.